CASE REPORT article
Front. Oncol.
Sec. Cancer Immunity and Immunotherapy
This article is part of the Research TopicAdvancing Next-Generation Immunotherapy and Biomarker Discovery: Pioneering the Future of Treatment Strategies in Solid TumorsView all 6 articles
Multimodal Immunotherapeutic Regimen (Envafolimab + Chemotherapy + Radiotherapy) for Four Synchronous Primary Malignant Neoplasms: A Case Report of 33-Month Survival and Implications for Tumor Immunology
Provisionally accepted
- 1Hebei General Hospital Affiliated to Hebei Medicine University, Shijiazhuang, China
- 2Fourth Hospital of Hebei Medical University, Shijiazhuang, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Multiple Primary Malignant Neoplasms (MPMNs) are defined as the presence of two or more independent malignant tumors in the same patient, either simultaneously or sequentially, presenting substantial diagnostic and therapeutic challenges. In recent years, immunotherapy—an emerging therapeutic modality—has shown notable clinical efficacy across a range of malignancies. This article reports a case of a patient with four concurrent primary malignancies who attained long-term survival following treatment with envafolimab injection. Using this case as a foundation, we discuss recent advances in immunotherapy for MPMNs, covering its mechanisms of action, clinical efficacy, therapeutic strategies, and current challenges. The goal is to provide a theoretical basis for clinical practice and identify future research directions.
Keywords: chemotherapy, clinical efficacy, Immunotherapy, Multiple primary malignant neoplasms, Treatmentoutcomes
Received: 17 Oct 2025; Accepted: 16 Dec 2025.
Copyright: © 2025 Liu, Zhang, Zhang, Duan, Gao, Zhang and Zhao. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Xuejuan Duan
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.